Monday, June 16, 2025

Latest

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the filing of a provisional patent application in the US for the novel use of ketamine as a potential treatment for Type 2 diabetes and obesity.

The filing of the patent for the indication follows the company evaluating various indications with panaceAI, which is the firms artificial intelligence platform. The platform has reportedly discovered protein bindings and interactions with ketamine that have lead to the compound being a potential treatment for diabetes and obesity. The tech is also reportedly currently evaluating DMT, MDMA, and LSD for future partnering opportunities and clinical development.

An application with the FDA has also been submitted for the use of ketamine as a potential treatment for parkinsons disease under an investigation new drug designation. If accepted, the company intends to expand the phase 2 clinical trial to include these new indications.

“We continue to focus on building our patent and product portfolio of prescription-based psychedelics through our drug repurposing and delivery methods for unmet medical needs. Our strategy is to investigate ketamine in FDA Phase 2 clinical trials for Parkinson’s disease and depression and with panaceAI™, we aim to find new uses of psychedelics, such as ketamine, psilocybin, DMT, MDMA and LSD, and incorporate them into our proprietary microneedle patch delivery system.”

Fabio Chianelli, CEO of PharmaTher

PharmaTher last traded at $0.24 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

First Majestic Silver: The Santa Elena Mine

Equinox Gold: Guidance Cut After Issues At Greenstone

Simply Solventless Q4 Earnings: So Much For Guidance

Recommended

Power Metallic Secures Jabal Baudan Project In Saudi Arabia

NexGen Energy Receives Approval For Site Expansion At Rook I Project

Related News

PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA...

Tuesday, May 25, 2021, 09:00:24 AM

Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing...

Thursday, October 15, 2020, 09:02:27 AM

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with...

Friday, September 24, 2021, 08:28:12 AM

Pharmather Enters Exclusive Arrangement For Psychedelic Delivery Tech

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive license...

Thursday, October 22, 2020, 08:13:19 AM

PharmaTher Applies For Pre-IND Meeting With US FDA For Ketabet

PharmaTher Holdings (CSE: PHRM) this morning announced that it continues to push forward with the...

Tuesday, June 15, 2021, 08:14:25 AM